



RESEARCH PROGRESS REPORT SUMMARY

Grant 02441: Evaluation of a New Vaccine for Canine Brucellosis

Principal Investigator: Angela Arenas, DVM, PhD

Research Institution: Texas A&M AgriLife Research

Grant Amount: \$67,524.00

Start Date: 3/1/2018 **End Date:** 8/31/2019

Progress Report: End-Year 1

Report Due: 2/28/2019 **Report Received:** 3/25/2019

(The content of this report is not confidential and may be used in communications with your organization.)

Original Project Description:

Canine infection by *Brucella* spp. constitutes a serious problem for dog breeders and pet owners, leading to the economic burden associated with reproductive loss and veterinary care. Canine brucellosis is also considered a public health concern because of its potential to be transmitted to humans. Within the U.S., the disease has reemerged due to the chronic persistence of the organism, low dose for infection, low sensitivity and specificity of the current diagnostic tests, and most importantly, the lack of a protective vaccine for dogs. Historically in the U.S., brucellosis control efforts for cattle, sheep, goats and domestic pigs have been successful mainly due to the availability of protective and efficacious vaccines. The goal of the proposed research is to develop a brucellosis vaccine that is safe, stable, free of side effects and efficacious for dogs. Previous AKC CHF funding (Grant #02275-A) has permitted the investigators to successfully engineer a promising live attenuated vaccine candidate denominated *B. canis* RM666ΔvjbR. This study will further investigate the ability of the vaccine candidate to induce appropriate immunity prior to its testing in dogs and will also develop a diagnostic assay capable of differentiating naturally infected vs vaccinated animals, necessary for mass vaccination. The development of a safe and highly protective brucellosis vaccine for dogs, will significantly impact owners, breeders and human health by limiting the spread of the disease.

Publications:

Hensel M, Negron M, Arenas-Gamboa AM. 2018. Brucellosis in dogs and public health risk. *Emerging Infectious Diseases*. Vol. 24, No.8, pp. 1401-1406. https://wwwnc.cdc.gov/eid/article/24/8/17-1171_article



Presentations: None at this time.

Report to Grant Sponsor from Investigator:

Canine infection by *Brucella* spp. constitutes a serious problem for dog breeders and pet owners, leading to the economic burden associated with reproductive loss and veterinary care. Canine brucellosis is also considered a public health concern because of its potential to be transmitted to humans. Within the US, the disease has reemerged due to the chronic persistence of the organism, low dose for infection, low sensitivity and specificity of the current diagnostic tests, and most importantly the lack of a protective vaccine for canine use. Historically in the US, brucellosis control efforts for cattle, sheep, goats and domestic pigs have been successful mainly due to the availability of protective and efficacious vaccines. The goal of our research is to develop a brucellosis vaccine that is safe, stable, free of side effects and efficacious for dogs. Towards this goal, previous funding (AKC CHF Grant- 2275-A) has permitted us to successfully engineer a promising live attenuated vaccine candidate denominated *B. canis* RM666ΔvjbR. Initial in vitro studies have demonstrated that this candidate is highly attenuated in canine macrophages as well as laboratory animals. In this study, we demonstrated that the RM-666ΔvjbR vaccine candidate induces a robust cellular immune response capable of protecting against infection and that this vaccine will also provide the means to differentiate vaccinated from naturally infected animals.